Parkinsonism Clinical Trial
Official title:
Measurement of Gait Using the Opal APDM and an Instrumented Gait Mat in Persons With Parkinsonism
NCT number | NCT02064543 |
Other study ID # | STU 072012-090 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 2013 |
Est. completion date | January 2017 |
Verified date | September 2019 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The project is a prospective trial comparing Zeno/GAITRite and APDM® in a cohort of persons
living with parkinsonian disorders. Ambulatory patients with a parkinsonian syndrome and who
are able to provide informed consent will participate in the assessments.
Outcome variables include selected gait and balance parameters such as cadence, gait-cycle,
stride-length, stride-velocity, turning duration, turning steps, postural sway and
anticipatory postural control. These parameters will be measured by the portable inertial
sensors developed by APDM® and the Zeno/GaitRite.
Status | Completed |
Enrollment | 24 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria 1. Adults between the ages of 18 and 80 years of age with a primary diagnosis of PD and similar parkinsonian syndromes 2. Individuals able to walk 100 feet independently, with or without the use of an assistive device (walker, cane) and follow simple instructions. 3. Individuals with sufficient physiological systemic support to participate in the study protocol Exclusion Criteria 1. Inability to speak English secondary to the need to understand and follow multistep directions 2. A secondary diagnosis (musculoskeletal, cardiopulmonary, neurological) that excludes participation in the study 3. Inability to ambulate 100 feet independently with or without an assistive device. 4. Inability to follow simple instructions necessary for completion of the testing tasks. |
Country | Name | City | State |
---|---|---|---|
United States | UT Southwestern Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | gait parameters | Outcome variables include selected gait and balance such as cadence | one year | |
Primary | gait parameters | Outcome variables include selected gait and balance such as stride-length | one year | |
Primary | gait parameters | Outcome variables include selected gait and balance such as stride-velocity | one year | |
Primary | gait parameters | Outcome variables include selected gait and balance such as turning duration | one year | |
Primary | gait parameters | Outcome variables include selected gait and balance such as turning steps | one year | |
Primary | gait parameters | Outcome variables include selected gait and balance such as postural sway | one year | |
Primary | gait parameters | Outcome variables include selected gait and balance such as anticipatory postural control | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
Active, not recruiting |
NCT05127057 -
Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)
|
N/A | |
Enrolling by invitation |
NCT01453127 -
DaTSCAN Imaging in Aging and Neurodegenerative Disease
|
Phase 4 | |
Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
Completed |
NCT03314610 -
Effect of Need to Void on Parkinsonian Gait
|
||
Recruiting |
NCT05506891 -
Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy
|
Phase 2 | |
Completed |
NCT00950196 -
Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
|
Phase 4 | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Enrolling by invitation |
NCT05514106 -
MIBG in Aging and Neurologic Disorders
|
Phase 4 | |
Completed |
NCT01581645 -
Mobilaser Study to Help With People Who Are Having Problems With Their Gait
|
Phase 0 | |
Not yet recruiting |
NCT00767546 -
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
|
Phase 1 | |
Completed |
NCT02214862 -
2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
|
Phase 0 | |
Recruiting |
NCT04518059 -
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
|
||
Completed |
NCT03076671 -
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
|
N/A | |
Withdrawn |
NCT01329926 -
Molecular Analysis of Human Neural Stem Cells
|
||
Terminated |
NCT00745030 -
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
|
N/A | |
Completed |
NCT04222218 -
Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT03386669 -
Novel Neuroimage Study in Tauopathies With Parkinsonism
|
Phase 2 | |
Active, not recruiting |
NCT05308485 -
Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease
|